AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32757149 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral remimazolam
Number of subjects: 46
Study 35993590 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI with PI-RADS ≤2
Number of subjects: 431
Study 35993590 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 431
Study 35765566 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS), two one-hour sessions daily for four weeks at suprathreshold intensities.
Number of subjects: 13
Study 35765566 — intervention group
Group type: COMPARATOR
Intervention: Sham control (not explicitly detailed in the abstract).
Number of subjects: 13
Study 33569570 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg QID elenbecestat
Number of subjects: 9758
Study 33569570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9758
Study 32729923 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nitrate beetroot juice (∼400 mg nitrate) and folic acid (∼5 mg folic acid) (N + F)
Number of subjects: 47
Study 32729923 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nitrate beetroot juice and placebo (N + P)
Number of subjects: 47
Study 32729923 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice and placebo (P + P)
Number of subjects: 47
Study 35511890 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (daily oral starting at 25 mg, increasing every 8 weeks for 6 months)
Number of subjects: 25
Study 35511890 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 25
Study 35511890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 35004534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide
Number of subjects: 82
Study 35004534 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline solution (placebo)
Number of subjects: 82
Study 34779234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4018
Study 34779234 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 4018
Study 34779234 — intervention group
Group type: COMPARATOR
Intervention: LRC
Number of subjects: 4018
Study 33471739 — intervention group
Group type: EXPERIMENTAL
Intervention: No oral calcium or calcitriol supplementation (test group)
Number of subjects: 56
Study 33471739 — intervention group
Group type: COMPARATOR
Intervention: Oral calcium and calcitriol supplementation (control group)
Number of subjects: 56
Study 35508349 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred consent procedures in the ACROBAT pilot trial
Number of subjects: 10
Study 35508349 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment process by research midwives and clinical trials practitioners
Number of subjects: 10
Study 35508349 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication of trial information to women
Number of subjects: 10
Study 35508349 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant information complexity
Number of subjects: 10
Study 35508349 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns regarding deferred consent procedures
Number of subjects: 10
Study 33909896 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-shifting exercise to the nonparetic side on an inclined surface (5 degrees)
Number of subjects: 52
Study 33909896 — intervention group
Group type: COMPARATOR
Intervention: Control group performed the exercise on a flat surface
Number of subjects: 52
Study 35887534 — intervention group
Group type: EXPERIMENTAL
Intervention: DehydraTECH2.0 CBD formulation
Number of subjects: 70
Study 35887534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 36239048 — intervention group
Group type: EXPERIMENTAL
Intervention: imeglimin
Number of subjects: 59
Study 32046199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive analgesia, multimodal analgesia, and analgosedation
Number of subjects: 216
Study 32046199 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs administered on demand
Number of subjects: 216
Study 32046199 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs from Steps 2 and 3 of the WHO analgesic ladder
Number of subjects: 216
Study 32965464 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating financial incentives
Number of subjects: 0
Study 32965464 — intervention group
Group type: EXPERIMENTAL
Intervention: Deescalating financial incentives
Number of subjects: 0
Study 32965464 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no incentive)
Number of subjects: 0
Study 32026297 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% centbucridine
Number of subjects: 56
Study 32026297 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine
Number of subjects: 56
Study 35901040 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect School intervention
Number of subjects: 9
Study 34380322 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 2185
Study 34380322 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 2185
Study 32365226 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg weekly) plus Cetuximab (400/250 mg/m2 weekly)
Number of subjects: 80
Study 32365226 — intervention group
Group type: COMPARATOR
Intervention: Temsirolimus alone
Number of subjects: 80
Study 35395734 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-based education program (5 sessions)
Number of subjects: 86
Study 35395734 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 86
Study 33089943 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (I)
Number of subjects: 185
Study 33089943 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + SMS group (I)
Number of subjects: 185
Study 33089943 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 185
Study 33977342 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventionist-guided (IG) weight loss intervention
Number of subjects: 246
Study 33977342 — intervention group
Group type: COMPARATOR
Intervention: Self-guided (SG) weight loss intervention
Number of subjects: 246
Study 32030780 — intervention group
Group type: EXPERIMENTAL
Intervention: A annua sublingual immunotherapy (SLIT) for 32 weeks
Number of subjects: 71
Study 32030780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 32030780 — intervention group
Group type: EXPERIMENTAL
Intervention: A annua sublingual immunotherapy (SLIT) for 16 weeks
Number of subjects: 71
Study 32030780 — intervention group
Group type: EXPERIMENTAL
Intervention: A annua sublingual immunotherapy (SLIT)
Number of subjects: 71
Study 36297099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C (HDIVC)
Number of subjects: 167
Study 36297099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 32111126 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D system for treating macular holes (MH)
Number of subjects: 4
Study 32111126 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D system for treating primary rhegmatogenous retinal detachment (RRD)
Number of subjects: 4
Study 32111126 — intervention group
Group type: COMPARATOR
Intervention: Traditional microscopy for treating macular holes (MH)
Number of subjects: 4
Study 32111126 — intervention group
Group type: COMPARATOR
Intervention: Ocular viewing for treating primary RRD
Number of subjects: 4
Study 36151448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound therapy combined with drug therapy (SDT)
Number of subjects: 44
Study 36151448 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (DT)
Number of subjects: 44
Study 33641346 — intervention group
Group type: EXPERIMENTAL
Intervention: LT-5%
Number of subjects: 11
Study 33641346 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta50
Number of subjects: 11
Study 33641346 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSS-5%
Number of subjects: 11
Study 33641346 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSSp
Number of subjects: 11
Study 33641346 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSS+5%
Number of subjects: 11
Study 33641346 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSS15
Number of subjects: 11
Study 33641346 — intervention group
Group type: EXPERIMENTAL
Intervention: MLSS45
Number of subjects: 11
Study 32285195 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care enhanced with ultrasound measurements of the diaphragm
Number of subjects: 32
Study 32285195 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 32
Study 32285195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Intervention and Control groups
Number of subjects: 32
Study 35867135 — intervention group
Group type: EXPERIMENTAL
Intervention: High albumin + IVIG treatment group
Number of subjects: 198
Study 35867135 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham PE)
Number of subjects: 198
Study 34369618 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored mindfulness-based program (MBP) for resident physicians; 8-week intervention followed by a 4-month maintenance phase.
Number of subjects: 147
Study 34369618 — intervention group
Group type: COMPARATOR
Intervention: Active control group received the coursebook for self-study.
Number of subjects: 147
Study 36173046 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative home visit intervention (3-month program, 6 sessions, 1 session every 2 weeks)
Number of subjects: 60
Study 36173046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visit intervention)
Number of subjects: 60
Study 36173046 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative home visit intervention
Number of subjects: 60
Study 33958216 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth visits
Number of subjects: 200
Study 33958216 — intervention group
Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 200
Study 32868350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 181
Study 35513899 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily fixed combination of Bimatoprost 0.01%, Brimonidine 0.15%, and Timolol 0.5%
Number of subjects: 30
Study 35513899 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily fixed combination of Bimatoprost 0.01%, Brimonidine 0.15%, and Timolol 0.5%
Number of subjects: 30
Study 35513899 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily fixed combination
Number of subjects: 30
Study 35513899 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily fixed combination
Number of subjects: 30
Study 34849580 — intervention group
Group type: EXPERIMENTAL
Intervention: Native recipient portal vein (RPV)
Number of subjects: 122
Study 34849580 — intervention group
Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 122
Study 34849580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RPV and PTFE
Number of subjects: 122
Study 34585482 — intervention group
Group type: EXPERIMENTAL
Intervention: SlowMo intervention (eight‐session digitally supported reasoning intervention)
Number of subjects: 362
Study 34585482 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI involvement
Number of subjects: 362
Study 32035516 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E and ALVAC-HIV (vCP1521) at month 12
Number of subjects: 367
Study 32035516 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E alone at month 12
Number of subjects: 367
Study 32035516 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E and ALVAC-HIV at month 15
Number of subjects: 367
Study 32035516 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E and ALVAC-HIV at month 18
Number of subjects: 367
Study 32035516 — intervention group
Group type: COMPARATOR
Intervention: No late boost (group 1)
Number of subjects: 367
Study 32035516 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed boosting (groups 2, 3, 4a, and 4b)
Number of subjects: 367
Study 35150194 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique A (shallow injection/3 aliquots)
Number of subjects: 63
Study 35150194 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique D (deep and shallow injections/5 aliquots)
Number of subjects: 63
Study 35150194 — intervention group
Group type: EXPERIMENTAL
Intervention: Techniques A, D, and E
Number of subjects: 63
Study 33549750 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived physical health QoL
Number of subjects: 135
Study 33549750 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived daily living activities
Number of subjects: 135
Study 33549750 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived pain and discomfort
Number of subjects: 135
Study 33549750 — intervention group
Group type: EXPERIMENTAL
Intervention: Global neuroimaging values
Number of subjects: 135
Study 33549750 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-wise analyses
Number of subjects: 135
Study 33549750 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction for objective physical health and physical activity measures
Number of subjects: 135
Study 33549750 — intervention group
Group type: EXPERIMENTAL
Intervention: Global brain perfusion and global amyloid deposition
Number of subjects: 135
Study 32665479 — intervention group
Group type: EXPERIMENTAL
Intervention: PP-MI intervention
Number of subjects: 60
Study 32665479 — intervention group
Group type: COMPARATOR
Intervention: MI-enhanced behavioral counseling
Number of subjects: 60
Study 616562397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cooling by means of water immersion (20.3 ± 0.3°C) for 60 min
Number of subjects: 8
Study 616562397 — intervention group
Group type: COMPARATOR
Intervention: Control condition: remained seated for 60 min in a laboratory (20.2 ± 1.7°C and 60.2 ± 2.5% r.h.)
Number of subjects: 8
Study 33794353 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Drug Management Module (DMM)
Number of subjects: 34
Study 33794353 — intervention group
Group type: COMPARATOR
Intervention: Manual process
Number of subjects: 34
Study 32067629 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual single-dose azithromycin
Number of subjects: 1200
Study 32067629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 34087948 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (OM) 25 mg modified release (MR) tablets under fed state
Number of subjects: 73
Study 34087948 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (OM) 37.5 mg modified release (MR) tablets under fed state
Number of subjects: 73
Study 34087948 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (OM) 50 mg modified release (MR) tablets under fed state
Number of subjects: 73
Study 34087948 — intervention group
Group type: COMPARATOR
Intervention: Two 25 mg OM MR tablets
Number of subjects: 73
Study 34922039 — intervention group
Group type: EXPERIMENTAL
Intervention: Separated action effects (action-effect condition)
Number of subjects: 0
Study 34922039 — intervention group
Group type: COMPARATOR
Intervention: Conjoined error feedback (feedback condition)
Number of subjects: 0
Study 34922039 — intervention group
Group type: COMPARATOR
Intervention: Single-task condition (baseline condition)
Number of subjects: 0
Study 35714786 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 2583
Study 35714786 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg
Number of subjects: 2583
Study 35714786 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2583
Study 36261162 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial voucher incentives (up to £400) in addition to usual support from stop smoking services
Number of subjects: 944
Study 36261162 — intervention group
Group type: COMPARATOR
Intervention: Standard stop smoking services (control group)
Number of subjects: 944
Study 33652234 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave heating
Number of subjects: 30
Study 33652234 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoclave heating
Number of subjects: 30
Study 33652234 — intervention group
Group type: COMPARATOR
Intervention: Control (no thermal treatment)
Number of subjects: 30
Study 33444175 — intervention group
Group type: EXPERIMENTAL
Intervention: I-WOTCH multicomponent self-management intervention for tapering opioid doses
Number of subjects: 0
Study 33444175 — intervention group
Group type: COMPARATOR
Intervention: Best usual care
Number of subjects: 0
Study 34600734 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/GB 200/12/25 ?g (therapeutic)
Number of subjects: 32
Study 34600734 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/GB 400/12/25 ?g (therapeutic)
Number of subjects: 32
Study 34600734 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/GB 800/48/100 ?g (supratherapeutic)
Number of subjects: 32
Study 34600734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32382772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-based regimen
Number of subjects: 2954
Study 32382772 — intervention group
Group type: COMPARATOR
Intervention: Non-carfilzomib-based regimen
Number of subjects: 2954
Study 34168284 — intervention group
Group type: EXPERIMENTAL
Intervention: ixazomib-dexamethasone
Number of subjects: 168
Study 34168284 — intervention group
Group type: COMPARATOR
Intervention: physician’s choice
Number of subjects: 168
Study 34534429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg) plus platinum-based chemotherapy (with or without bevacizumab)
Number of subjects: 548
Study 34534429 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy (with or without bevacizumab)
Number of subjects: 548
Study 32892710 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian sample size calculation for snSMART
Number of subjects: 0
Study 32892710 — intervention group
Group type: COMPARATOR
Intervention: Frequentist method based on a weighted Z-statistic
Number of subjects: 0
Study 36427174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Number of subjects: 108
Study 36427174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 34419135 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat follow-up management
Number of subjects: 100
Study 34419135 — intervention group
Group type: COMPARATOR
Intervention: Traditional management
Number of subjects: 100
Study 32131641 — intervention group
Group type: EXPERIMENTAL
Intervention: patisiran 0.3 mg/kg
Number of subjects: 225
Study 32131641 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 225
Study 35305154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided methodologic approach (UMA)
Number of subjects: 143
Study 35305154 — intervention group
Group type: COMPARATOR
Intervention: Classical pubic approach (PA)
Number of subjects: 143
Study 35305154 — intervention group
Group type: COMPARATOR
Intervention: Inguinal approach (IA)
Number of subjects: 143
Study 34584851 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy (ICBT), guided self-help tailored to predominant symptomatology of PTSD or depression, duration not specified.
Number of subjects: 0
Study 34584851 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition, received delayed treatment at follow-up assessment.
Number of subjects: 0
Study 33142129 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 1147
Study 33142129 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge-eating disorder (BED)
Number of subjects: 1147
Study 33142129 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant-restrictive food intake disorder (ARFID)
Number of subjects: 1147
Study 33142129 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrained eating
Number of subjects: 1147
Study 33142129 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional eating
Number of subjects: 1147
Study 33142129 — intervention group
Group type: EXPERIMENTAL
Intervention: Picky eating
Number of subjects: 1147
Study 36307177 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-scope clip (OTSC)
Number of subjects: 100
Study 36307177 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 100
Study 32713721 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) with a hypoenergetic diet for 12 months
Number of subjects: 58
Study 32713721 — intervention group
Group type: COMPARATOR
Intervention: Hypoenergetic diet only for 12 months
Number of subjects: 58
Study 32299222 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided rate-adaptive pacing
Number of subjects: 83
Study 32299222 — intervention group
Group type: COMPARATOR
Intervention: Conventional age-guided rate-response programming
Number of subjects: 83
Study 32299222 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided heart rate settings
Number of subjects: 83
Study 32299222 — intervention group
Group type: COMPARATOR
Intervention: Conventional settings
Number of subjects: 83
Study 35915056 — intervention group
Group type: EXPERIMENTAL
Intervention: One Session Treatment (OST)
Number of subjects: 268
Study 35915056 — intervention group
Group type: COMPARATOR
Intervention: Multi-session Cognitive Behavioral Therapy (CBT)
Number of subjects: 268
Study 34403591 — intervention group
Group type: EXPERIMENTAL
Intervention: MindLight
Number of subjects: 117
Study 34403591 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 117
Study 32482712 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR) for 3 months followed by a 4-week weight maintenance phase
Number of subjects: 0
Study 32482712 — intervention group
Group type: COMPARATOR
Intervention: Stable weight maintenance (Control group)
Number of subjects: 0
Study 35752762 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) group (n=31)
Number of subjects: 62
Study 35752762 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC) group (n=31)
Number of subjects: 62
Study 35292074 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion on the navel once a week for three consecutive menstrual cycles
Number of subjects: 210
Study 35292074 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group) for 3 menstrual cycles
Number of subjects: 210